Back to Search
Start Over
A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients.
- Source :
-
Journal of thoracic disease [J Thorac Dis] 2020 Oct; Vol. 12 (10), pp. 6107-6111. - Publication Year :
- 2020
-
Abstract
- Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-1733). AC received speaker fees and grant consultancies by AstraZeneca, MSD, BMS, Roche, Novartis and Astellas. The other authors have no other conflicts of interest to declare.
Details
- Language :
- English
- ISSN :
- 2072-1439
- Volume :
- 12
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Journal of thoracic disease
- Publication Type :
- Editorial & Opinion
- Accession number :
- 33209443
- Full Text :
- https://doi.org/10.21037/jtd-20-1733